What GLP-1 actually does in your body

1. They mimic a hormone you already make

Your gut produces a hormone called GLP-1(glucagon-like peptide-1) after every meal. The job of that hormone is to tell your brain you're full, slow down how quickly food leaves your stomach, and tell your pancreas to release insulin in response to the glucose you just ate.

In people with obesity and type 2 diabetes, that signal is blunted. The hormone gets released, but in smaller amounts, and your body breaks it down within minutes. The natural “I'm full” signal never quite gets loud enough.

Semaglutide and tirzepatide are synthetic molecules that look almost identical to your own GLP-1 — with one important difference: they're engineered to stay in your bloodstream for about a weekinstead of a few minutes. That's why most people take them once a week, not daily.

2. They turn up the volume on three signals at once

Once in your blood, the medication does three things in parallel:

• Slows gastric emptying.Food sits in your stomach longer, so you feel physically full for longer. This is also why early side effects tend to be nausea or constipation — your gut is adjusting to a slower pace.
• Quiets food noise in the brain.Patients consistently describe a drop in “food noise” — the constant background loop of thinking about the next snack or meal. The hormone acts on the same brain regions that drive cravings.
• Improves insulin response.When you do eat, your pancreas releases insulin more efficiently and your liver releases less stored glucose. Blood sugar swings get smaller. That's why these drugs are also gold-standard for type 2 diabetes.

Tirzepatide does a fourth thing: it also activates a second hormone receptor called GIP, which is why head-to-head trials show slightly larger weight loss with tirzepatide than with semaglutide at comparable doses.

3. What kind of weight loss are we talking about?

Published phase-3 trials are remarkably consistent. In adults with obesity, the average weight loss over 68 weeks of treatment is:

For someone who weighs 90 kg, that's 13–18 kg of weight loss on average — not the upper bound, the average. Some people lose more, some less; lifestyle still matters.

The reason this is a big deal: no non-surgical intervention has ever come close to those numbers. Lifestyle programmes alone average 3–5%. Most older medications topped out at 5–10%.

4. What it isn't

This is the part most marketing skips.

• It's not a shortcut. The medication lowers your appetite so a healthier intake is achievable; you still have to eat enough protein, move regularly, and sleep properly for the weight you lose to be muscle-sparing and durable.
• It's not lifelong by default.If you stop taking it, appetite returns to baseline and most people regain ~two-thirds of the weight they lost within a year. This is true of nearly every chronic-condition medication (blood pressure pills, statins) — it doesn't mean the medication failed, it means obesity is a chronic disease.
• It's not for cosmetic weight loss.In India, prescribing guidelines (and your ZIVOLABS doctor) will look for a BMI in the obesity range, or in the overweight range with at least one weight-related condition like prediabetes or hypertension. If you don't meet clinical criteria, the doctor will say so.
• It's not risk-free.Nausea and constipation in the first weeks are common and usually fade. Pancreatitis, gallbladder problems, and rare allergic reactions are documented — which is exactly why this should be doctor-supervised, with weekly check-ins, not bought off a website.

5. Why “doctor-supervised” isn't marketing fluff

In countries where GLP-1 medications are easier to buy, the biggest problems clinicians report aren't about the medication itself — they're about how people are using it without supervision. Common patterns:

• Dose escalation too fast, leading to severe nausea and dehydration.
• Inadequate protein intake, leading to muscle loss along with the fat loss.
• Stopping abruptly, then rebounding hard.
• Taking it during pregnancy or alongside contraindicated medications because nobody asked.

All of these are preventable with a real consultation, a titration plan, and weekly check-ins. That's what your ZIVOLABS subscription covers — the medication is one part of the package; the supervision is the other.

What to do next

If you've read this far and you're wondering whether GLP-1 therapy is right for your body, your weight, and your medical history — that's exactly what our 5-minute qualification check is built for. You answer some honest questions about your health; a doctor reviews it; if you're a fit, you book a consult. If you're not, the doctor will say so and recommend what to do instead.

No pressure, no commitment, no card needed to find out.